Ravindra G Rathod¹, Pooja S Murkute¹*, Gajanan S Sanap² and Rahul R Pawar¹

¹Department of Pharmacognosy, LBYP College of D. Pharmacy (D. Pharm and B. Pharm) Aurangabad, BATU University, India
²Department of Pharmaceutics, LBYP College of D. Pharmacy (D. Pharm and B. Pharm) Aurangabad, BATU University, India

*Corresponding Author: Pooja S Murkute, Assistant Professor, Department of Pharmacognosy, LBYP College of D. Pharmacy (D. Pharm and B. Pharm) Aurangabad, BATU University, India.

Received: June 20, 2022 Published: July 14, 2022

Abstract

The present topic is focus on COVID-19 and the symptoms associated with the same. As we are familiar with Coronavirus (COVID-19), the infective agent ill health caused by the novel coronavirus SARS-CoV-2 has resulted in important morbidity and mortality across the planet since the primary cases were known in metropolis China, in Gregorian calendar month 2019. Current topic will have specific emphasis on classification related to COVID syndrome, also this will focus on Pathological condition of COVID-19. According to pathological inflammation it is found that There are instances of COVID-19 patients WHO remained positive for SARS-CoV-2 by reverse transcription period enzyme chain reaction (RT-PCR) take a look at for up to 3 months’ different studies have documented cases of prolonged SARS-CoV-2 shedding within the tract via quantitative RT-PCR for up to four months. Some severe pathological inflammations are Infection with SARS-CoV-2 unremarkably results in metastasis Symptoms typical of a pneumonia, as well as fever, Cough, dyspnea, and inflammatory disease however conjointly, curiously, dysomia and dysgeusia that suggests that the virus Is tropism in an exceedingly retrospective case series of 214 patients urban center, China, a high incidence of medical specialty symptoms was seen the actual pathological inflammation to every organ is serious about COVID infection.

Keywords: Coronavirus (COVID-19); COVID-19-Associated Aeropathy (COVAN); Faecal Bacterium Prausnitzii, Renin-angiotensin-aldosterone System, Dermatologic Sequelae; Hypoxemia; Bilateral Pulmonic

References

1. Amenta Eva M., et al. "Postacute COVID-19: an overview and approach to classification”. Open Forum Infectious Diseases US: Oxford University Press 7.12 (2020).
2. Fernández-de-Las-Peñas César., et al. "Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification”. International Journal of Environmental Research and Public Health5 (2021): 2621.
3. Stratton Charles W., et al. "Pathogenesis‐directed therapy of 2019 novel coronavirus disease”. Journal of Medical Virology3 (2021): 1320-1342.
4. Ortelli Paola., et al. "Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom”. Journal of the Neurological Sciences420 (2021): 117271.
5. Garcia-Oscos Francisco., et al. "The stress-induced cytokine interleukin-6 decreases the inhibition/excitation ratio in the rat temporal cortex via trans-signaling”. Biological Psychiatry7 (2012): 574-582.
6. Ritchie Karen., et al. "The cognitive consequences of the COVID-19 epidemic: collateral damage?" Brain Communications2 (2020): fcaa069.
7. Wostyn Peter. "COVID-19 and chronic fatigue syndrome: Is the worst yet to come?”. Medical Hypotheses146 (2021): 110469.
8. Maltezou Helena C., et al. "Post-COVID syndrome: an insight on its pathogenesis”. Vaccines5 (2021): 497.
9. Hayden Melvin R. "An immediate and long-term complication of COVID-19 may be type 2 diabetes mellitus: the central role of β-cell dysfunction, apoptosis and exploration of possible mechanisms”. Cells 11 (2020): 2475.
10. Sathish Thirunavukkarasu., et al. "Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes”. Diabetes and Metabolism2 (2021): 101204.
11. Abrams Joseph Y., et al. "Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review”. The Journal of Pediatrics226 (2020): 45-54.
12. Morris Sapna Bamrah., et al. "Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection—United Kingdom and United States, March–August 2020”. Morbidity and Mortality Weekly Report40 (2020): 1450.
13. Carmo Anália., et al. "Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19”. Journal of Medical Virology10 (2020): 2227-223.
14. Kandetu Theo-Ben., et al. "Persistence of positive RT-PCR results for over 70 days in two travelers with COVID-19”. Disaster Medicine and Public Health Preparedness (2020): 1-2.
15. Vibholm Line K., et al. “SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses”. EBioMedicine 64 (2021): 103230.
16. Wang Xingyu., et al. "Long-term existence of SARS-CoV-2 in COVID-19 patients: host immunity, viral virulence, and transmissibility”. Virologica Sinica6 (2020): 793-802.
17. Hirotsu Yosuke., et al. “Analysis of a persistent viral shedding patient infected with SARS-CoV-2 by RT-qPCR, FilmArray Respiratory Panel v2. 1, and antigen detection”. Journal of Infection and Chemotherapy 2 (2021): 406-409.
18. Li Qian., et al. “Prolonged shedding of severe acute respiratory syndrome coronavirus 2 in patients with COVID-19”. Emerging Microbes and Infections1 (2020): 2571-2577.
19. Park Soo-kyung., et al. “Detection of SARS-CoV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea”. Clinical Gastroenterology and Hepatology7 (2021): 1387-1394.
20. Wu Yongjian., et al. “Prolonged presence of SARS-CoV-2 viral RNA in faecal samples”. The lancet Gastroenterology and Hepatology5 (2020): 434-435.
21. Gaebler Christian., et al. "Evolution of antibody immunity to SARS-CoV-2”. Nature7851 (2021): 639-644.
22. Karlsson Annika C., et al. “The known unknowns of T cell immunity to COVID-19”. Science Immunology53 (2020): eabe8063.
23. Ehrenfeld M., et al. “COVID-19 and autoimmunity”. Autoimmunity Reviews (2020).
24. Lui David Tak Wai., et al. “Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19”. The Journal of Clinical Endocrinology and Metabolism2 (2021): e926-e935.
25. Muller Ilaria., et al. “SARS-CoV-2-related atypical thyroiditis”. The Lancet Diabetes and Endocrinology9 (2020): 739-741.
26. Li Qian., et al. “The pathogenesis of thyroid autoimmune diseases: new T lymphocytes–cytokines circuits beyond the Th1− Th2 paradigm”. Journal of Cellular Physiology3 (2019): 2204-2216.
27. Bansal Manish. “Cardiovascular disease and COVID-19”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews3 (2020): 247-250.
28. Vaidya A and R Dluhy. "Hyperaldosteronism”. Endotext. South Dartmouth (MA): MDText. com, Inc. (2000).
29. Young Barnaby Edward., et al. "Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore”. JAMA15 (2020): 1488-1494.
30. Yao Xueting., et al. “In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)”. Clinical Infectious Diseases15 (2020): 732-739.
31. Soubrier Martin., et al. “Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: a post hoc analysis”. Rheumatology and Therapy1 (2017): 133-149.
32. Tan Weiyi and Jamil Aboulhosn. “The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease”. International Journal of Cardiology 309 (2020): 70-77.
33. Matuschak George M and Andrew J Lechner. "Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment”. Missouri Medicine4 (2010): 252.
34. Walkey Allan J., et al. "Acute respiratory distress syndrome: epidemiology and management approaches”. Clinical Epidemiology4 (2012): 159.
35. Williams Andrew E and Rachel C Chambers. “The mercurial nature of neutrophils: still an enigma in ARDS?”. American Journal of Physiology-Lung Cellular and Molecular Physiology3 (2014): L217-L230.
36. Burnham Ellen L., et al. “The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance”. European Respiratory Journal1 (2014): 276-285.
37. Kouzbari, Karim., et al. “Oscillatory shear potentiates latent TGF-β1 activation more than steady shear as demonstrated by a novel force generator”. Scientific Reports1 (2019): 1-8.
38. Sierpiński Radosław., et al. “Gender differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders among 1,942 non-hospitalized patients with COVID-19”. Polish Archives of Internal Medicine 130 (2020): 501-505.
39. Mao Ling., et al. “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China”. JAMA Neurology6 (2020): 683-690.
40. Al-Aly., et al. “High-dimensional characterization of post-acute sequelae of COVID-19”. Nature 7862 (2021): 259-264.
41. Huang Chaolin., et al. "6-month consequences of COVID-19 in patients discharged from hospital: a cohort study”. The Lancet10270 (2021): 220-232.
42. Dennis Andrea., et al. “Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study”. BMJ Open3 (2021): e048391.
43. Stockmann Helena., et al. “High rates of long-term renal recovery in survivors of coronavirus disease 2019–associated acute kidney injury requiring kidney replacement therapy”. Kidney International 4 (2021): 1021-1022.
44. Al-Aly., et al. "High-dimensional characterization of post-acute sequelae of COVID-19”. Nature7862 (2021): 259-264.
45. Garg Mahendra K., et al. "Endocrine involvement in COVID-19: mechanisms, clinical features, and implications for care”. Indian Journal of Endocrinology and Metabolism5 (2020): 381.
46. Rubino Francesco., et al. “New-onset diabetes in Covid-19”. New England Journal of Medicine8 (2020): 789-790.
47. Chaudhary Rahul., et al. “Personalizing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry”. Thrombosis and Haemostasis11 (2020): 1594-1596.
48. Sher Leo. “Are COVID-19 survivors at increased risk for suicide?”. Acta Neuropsychiatrica5 (2020): 270-270.
49. Sher Leo. “Post-COVID syndrome and suicide risk”. QJM: An International Journal of Medicine2 (2021): 95-98.
50. Al-Aly., et al. “High-dimensional characterization of post-acute sequelae of COVID-19”. Nature7862 (2021): 259-264.

Citation

Citation: Pooja S Murkute., et al. “Post Symptoms, Complications and Pathogenesis of SARS-Severe Acute Respiratory Syndrome Generated COVID-19". Acta Scientific Pharmacology 3.8 (2022): 12-20.

Copyright

Copyright: © 2022 Pooja S Murkute., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.